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ABSTRACT
As the second most common malignant bone tu-
mor in children and adolescents, Ewing sarcoma is
initiated and exacerbated by a chimeric oncopro-
tein, most commonly, EWS-FLI1. In this study, we
apply epigenomic analysis to characterize the tran-
scription dysregulation in this cancer, focusing on
the investigation of super-enhancer and its asso-
ciated transcriptional regulatory mechanisms. We
demonstrate that super-enhancer-associated tran-
scripts are significantly enriched in EWS-FLI1 tar-
get genes, contribute to the aberrant transcriptional
network of the disease, and mediate the exceptional
sensitivity of Ewing sarcoma to transcriptional in-
hibition. Through integrative analysis, we identify
MEIS1 as a super-enhancer-driven oncogene, which
co-operates with EWS-FLI1 in transcriptional regula-
tion, and plays a key pro-survival role in Ewing sar-
coma. Moreover, APCDD1, another super-enhancer-
associated gene, acting as a downstream target of
both MEIS1 and EWS-FLI1, is also characterized as
a novel tumor-promoting factor in this malignancy.
These data delineate super-enhancer-mediated tran-
scriptional deregulation in Ewing sarcoma, and un-
cover numerous candidate oncogenes which can be
exploited for further understanding of the molecular
pathogenesis for this disease.
INTRODUCTION
Ewing sarcoma is the second most common and devastat-
ing primary bone malignancy that arises predominantly in
children and adolescents. Despite progress in its treatment
over the past decades, the survival rate of its patients is not
satisfactory, pointing to the urgent need for more effective
therapies centered on the molecular basis of the cancer (1–
3).
Recent studies have highlighted that the disease-defining
fusion protein EWS-FLI1 utilizes directly divergent chro-
matin remodeling mechanisms to either activate or repress
enhancer elements in Ewing sarcoma (4,5). Therefore, char-
acterization of epigenomic deregulation in Ewing sarcoma
may provide innovative insights into the pathophysiology of
this cancer and offer new therapeutic approaches.
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Interestingly, studies have noted that relative to typical
enhancers, transcripts associated with super-enhancers are
enriched for active EWS-FLI1 binding motifs (6). By reg-
ulating cell-type specific genes, super-enhancer is a large
cluster of cis-regulatory DNA elements densely bound by
transcription factors and cofactors, playing critical roles in
defining cell fate and identity (7,8). Histone marks such as
H3K27ac, H3K4me1 and the transcription cofactor p300
often are used to define super-enhancers (4,6,9–11). Impor-
tantly, super-enhancers frequently drive high-level expres-
sion of prominent oncogenes in cancer cells. In particular,
we and others have recently shown that the expression of
super-enhancer-associated genes is disproportionately vul-
nerable to transcriptional perturbation, mediating the ad-
diction of cancer cells to high-level transcription (10–14).
In the current study, we observed that Ewing sarcoma
cells were sensitive to transcriptional perturbation, medi-
ated by CDK7 suppression. Analyses of four cell lines
and three primary tumors established the super-enhancer
landscape of Ewing sarcoma, and revealed that super-
enhancer-associated genes were exceptionally sensitive to
inhibition of CDK7. Further investigation based on the bi-
ological attributes of super-enhancers identifiedMEIS1 as a
novel oncogenic transcription factor that played a key pro-
survival role in Ewing sarcoma, via activating the transcrip-
tion of APCDD1 cooperatively with EWS-FLI1.
MATERIALS AND METHODS
Cell culture
Ewing sarcoma cell lines (A673, SKNMC, TC32, TC71,
EW8, TCC446 and EWS502) used in this study were de-
scribed previously (15,16). Briefly, they were grown in Dul-
becco’s modified Eagle’s medium (DMEM) containing 10%
fetal bovine serum (FBS) and 1% penicillin–streptomycin,
and kept at 37◦C with 5% CO2. The identity of all cell lines
was recently authenticated by short tandem repeat analysis.
All cells were tested to be free of mycoplasma contamina-
tion.
Antibodies, reagents and kits
The following antibodies were used in the current study:
CDK7 (Cell Signaling Technology, 2916), RNAPII CTD
S2 (Bethyl, A300–654A), RNAPII CTD S5 (Bethyl, A300–
655A), RNAPII CTD S7 (Cell Signaling Technology,
13780), RNAPII (Santa Cruz, sc-899), MEIS1 (Abcam,
ab19867), APCDD1 (Novus Biologicals, NB110–92756SS),
FLI-1 (Santa Cruz Biotechnology, sc-53826), GAPDH
(Cell Signaling Technology, 5174), anti-mouse IgG-HRP
(Santa Cruz Biotechnology, sc-2005), anti-rabbit IgG-HRP
(Santa Cruz Biotechnology, sc-2004) and rabbit IgG Iso-
type Control (Invitrogen, 02–6102). Reagents and kits in-
cluded: THZ1 (ApexBio, A8882), FITC Annexin V Apop-
tosis Detection Kit (BD Biosciences), Dual-Luciferase
Reporter Assay System (Promega), BioT transfection
reagent (Bioland Scientific), Lipofectamine 2000 transfec-
tion reagent (Invitrogen), LipofectamineRNAiMAX trans-
fection reagent (Invitrogen), and siRNA pools targeting
MEIS1 and APCDD1 (Dharmacon, Supplementary Table
S1).
MTT cell proliferation assay
Cells were seeded into 96-well plates at a density of 3000–
4000 cells per well and cultured for indicated time course.
For THZ1 treatment, the cultural medium was replaced
with fresh complete medium containing either DMSO or
THZ1 at day 0 once the cells were attached to the plates.
Cell proliferation was measured by standard MTT assay as
described previously (17).
Apoptosis assay
Cell apoptosis was measured using flow cytometric analy-
sis of double staining with Annexin V and propidium io-
dide (PI) according to the manufacturer’s instructions (BD
Biosciences). Data were analyzed using FlowJo 7.6 software
(Tree Star).
Soft agar colony formation assay
Soft agar colony formation assay was performed to evaluate
the anchorage independent growth of Ewing sarcoma cells.
Briefly, a bottom layer solution (0.6% agarose in DMEM
with 10% FBS) was added into 12-well plate and solidified
before use. 1500 cells were then mixed with 500 l of top
layer solution (0.3% low melting agarose in DMEM with
10% FBS) and spread over the bottom layer. After solidi-
fied at 4◦C, 0.5 ml of feeder medium was added into each
well. The plates were kept in a 5% CO2 incubator at 37◦C
for 2 weeks. Colonies were stained with 0.01% crystal violet
in 4% paraformaldehyde/PBS and quantified using ImageJ
software.
Chromatin immunoprecipitation (ChIP) assay
To cross-link DNA and protein, 2 × 107 of A673 cells were
fixed with 1% formaldehyde for 10 min at room temper-
ature. Chromatin solution was prepared following a stan-
dard protocol (10). For immunoprecipitation, solubilized
chromatinwas incubatedwith 5g of anti-MEIS1 antibody,
anti-FLI-1 antibody, or IgG control overnight at 4◦C on a
rotating wheel. Antibody-chromatin complexes were subse-
quently pulled down by incubating with Dynabeads Pro-
tein G (Life Technologies) for 4 h at 4◦C. After reversal of
crosslink, RNase A as well as Proteinase K treatment, im-
munoprecipitated DNA was extracted with the Min-Elute
PCR purification kit (Qiagen), followed by qPCR analysis,
or DNA library preparation and sequencing onHiSeq 3000
platform. Primers for qPCR analysis are listed in Supple-
mentary Table S2.
qRT-PCR
Total RNA was extracted using RNeasy mini kit (Qiagen),
and 1 g aliquots were used for cDNA synthesis using the
qScript™ cDNA Synthesis Kit (Quanta Biosciences). The
cDNA templates were subjected to PCR amplification on
CFX96 qPCR System (Biorad). Expression of each gene
was normalized to GAPDH, and quantified using 2−delta(ct)
method. Primers are listed in Supplementary Table S3.
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Immunoblotting assay
Cells were lysed in RIPA lysis and extraction buffer
(Thermo Fisher Scientific), supplemented with proteinase
inhibitor cocktail and phosphatase inhibitor cocktail
(Roche) for 30 min on ice. Protein quantification was deter-
mined by Bradford assay. Immunoblotting was performed
using SDS-PAGE followed by protein transfer to PVDF
membrane (Bio-Rad). Primary antibodies were incubated
overnight in cold room. Secondary antibodies were incu-
bated for 1–2 h at room temperature. Indicated antibodies
are listed above.
Retroviral and lentiviral infections
Retroviral MSCV-PIG-MEIS1 plasmid and MSCV-PIG
control vector were generous gifts from Dr. Jianjun Chen
(University of Cincinnati, College of Medicine). Lentivi-
ral pLVX-DsRed-APCDD1 plasmid, and pLKO.1-puro
or pLKO-Tet-On vector based shRNAs targeting CDK7,
EWS-FLI1, MEIS1 and APCDD1 were constructed and
confirmed by DNA sequencing. All retroviral and lentivi-
ral particles were prepared in HEK293T cells. For retro-
viral particle preparation, MSCV-PIG-MEIS1 and pCL-
Eco packaging vector were co-transfected using BioT trans-
fection reagent. For lentiviral particle production, recom-
binant vectors were co-transfected with packaging vectors
(psPAX2 and pMD2.G). Supernatants containing viral par-
ticles were harvested 24, 48 and 72 h after transfection and
filtered (pore size: 0.45 m). To generate stable cell lines,
Ewing sarcoma cells were transduced with virus-containing
medium in the presence of 8g/mL polybrene for 16 hours,
and selected in 1g/ml puromycin for 48 h post-infection.
shRNA target sequences are listed in Supplementary Table
S4.
Luciferase reporter assay
Super-enhancer constituent elements (∼500 bp) were
cloned into the Firefly luciferase reporter vector pGL3-
Promoter (Promega). A673 and SKNMC cells were trans-
fected using Lipofectamine 2000 transfection reagent. A
Renilla luciferase control plasmid was co-transfected as a
normalization control. Luciferase activity wasmeasured us-
ing the Dual-Luciferase Reporter Assay System (Promega).
Primers used for PCR amplification of luciferase reporter
vector construction are listed in Supplementary Table S5.
Identification and analysis of super-enhancers
H3K27ac ChIP-seq raw data generated in four Ewing sar-
coma cell lines and three primary tumors (4,6) were re-
trieved from NCBI Gene Expression Omnibus (GEO) or
generously shared by Dr Kimberly Stegmaier (Harvard
Medical School). Data were re-analyzed to identify super-
enhancers based on the method previously described (8).
Gene ontology (GO) and gene set enrichment analysis
(GSEA)
GO analysis was performed using consensusPath DB
(cpdb.molgen.mpg.de). Significant enriched biological pro-
cesses were defined as P< 0.01. GSEA for super-enhancer-
and typical-enhancer-associated transcripts of Ewing sar-
coma was performed as previously described (10).
Motif analysis
DNA segments predicted to be bound by MEIS1 in Ewing
sarcoma were extracted for motif analysis by Homer (http:
//homer.ucsd.edu/homer/motif/). Homer script findMotif-
sGenome.pl was run on all segments with augment ‘hg19-
size200-len10-noMotif ’to detect enrichment of known tran-
scription factor motifs. Homer results were further manu-
ally examined, and those motifs with high background en-
richment were removed.
RESULTS
THZ1 exerts potent anti-neoplastic effect in Ewing sarcoma
Our recent work in other cancer types demonstrated that
inhibiting transcriptional process can be exploited as a po-
tential therapeutic strategy (10,11). Given that transcrip-
tional dysregulation typifies the biology of Ewing sarcoma,
we first evaluated the anti-tumor effect of transcription in-
hibition in Ewing sarcoma cells by testing THZ1, which is a
newly developed covalent inhibitor of cyclin-dependent ki-
nase 7 (CDK7). We and others have recently reported the
growth inhibitory effects of THZ1 in multiple types of can-
cers via suppressing CDK7-dependent transcriptional acti-
vation (10–14,18). Dose-response experiments showed that
all seven representative Ewing sarcoma cell lines were highly
sensitive to THZ1 treatment, with IC50 values ranging from
28 to 49 nM (Figure 1A). In fact, these IC50 values in Ewing
sarcoma cells were lower than the majority of solid tumor
cells tested in the same setting (10,11,13,14,18). Depletion
of CDK7 expression by shRNAs confirmed that CDK7was
indispensable for the viability of Ewing sarcoma cells (Fig-
ure 1B).
In vitro proliferation and apoptosis assays subsequently
showed that THZ1 treatment led to profound reduction of
proliferation and massive induction of apoptosis in Ewing
sarcoma cells (Figure 1C, D).We next tested the anti-tumor
effect of THZ1 in NOD scid gamma (NSG) murine model,
where each mouse carried two explants formed by A673
cells. Mice bearing tumors were randomly divided into two
groups and treated with either vehicle or THZ1 twice daily
(10 mg/kg). Strikingly, THZ1 treatment completely abol-
ished tumor growth in vivo, highlighting the strong anti-
Ewing sarcoma property of this compound (Figure 1E-G).
Importantly, in these experimental mice, neither significant
loss of body weight (Figure 1H) nor other common toxic
effects (e.g. diarrhea, rash, etc. data not shown) were ob-
served, in agreement with our previous reports (10,11).
CDK7 inhibition elicits selective transcriptional repression in
Ewing sarcoma cells
We next probed the mechanisms underlying the sensitiv-
ity of Ewing sarcoma cells to THZ1. CDK7 phospho-
rylates RNA Polymerase II C-terminal domain (RNAP
IICTD), thereby regulating transcriptional initiation and
pause release, as well as elongation (19–21). Accordingly,
we observed a dose- and time-dependent decrease in RNAP
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Figure 1. THZ1 exhibits strong anti-neoplastic property against Ewing sarcoma. (A)Dose-response curves of 7 Ewing sarcoma cell lines to THZ1 treatment
for 72 hr. IC50 values were measured byMTT assay. Data were represented as mean± SD of three replicates. (B) A673 and SKMNC cells stably expressing
either CDK7-specific shRNAs or scrambled shRNA control (Scramble) were subjected to immunoblotting assay (upper panel) and colony formation assay
(lower panel). Bars represent mean± SD of three replicates (*** P< 0.001). (C) MTT assay and (D) apoptosis assay showing the effect of THZ1 treatment
on Ewing sarcoma cell lines at indicated time points. Bars represent mean ± SD of three replicates (**P < 0.01, ***P < 0.001). (E–G) THZ1 suppressed
the growth of A673 xenografts. (E) Images and (F) weights of resected tumors from both vehicle and THZ1 treatment groups at the end point. (G) Tumor
volumes of mice treated either with vehicle or THZ1. Data represent mean ± SD of each group (**P < 0.01, ***P < 0.001). (H) No significant loss of
body weight was observed in mice during treatment.
IICTD phosphorylation at both initiation-associated serine
5 (S5) and serine 7 (S7) as well as the elongation-associated
serine 2 (S2) in both A673 and SKNMC cells upon THZ1
treatment (Figure 2A, B).
The THZ1-induced transcriptional alterations in Ew-
ing sarcoma cells were further studied using whole-
transcriptome sequencing (RNA-Seq) in both A673 and
SKNMC cell lines, following treatment with 50 and 200
nM THZ1 for 6 hours. These concentrations and time
points were selected because they represented either lim-
ited (50 nM, low-dose) or substantial (200 nM, high-dose)
inhibition of RNAP IICTD phosphorylation (Figure 2A,
B). Of note, compared to high-dose treatment, low-dose
THZ1 elicited transcriptional inhibition in a more selec-
tive manner (Figure 2C, D; Supplementary Dataset S1). To
begin to understand the biological characteristics of tran-
scripts which were particularly sensitive to THZ1, Gene
ontology (GO) analysis was performed and those THZ1-
sensitive transcripts showed significant enrichment in cel-
lular processes including transcriptional regulation, DNA
repair, signal transduction and cell cycle regulation (Fig-
ure 2E). These results highlighted the prominent roles of
these THZ1-sensitive transcripts in Ewing sarcoma, and
suggested that they might be pivotal in mediating the ex-
ceptional sensitivity of Ewing sarcoma cells to CDK7 inhi-
bition.
Characterization of super-enhancer landscape in Ewing sar-
coma
Previouswork including ours has demonstrated that expres-
sion of super-enhancer-associated genes requires persistent
transcriptional activation; and thus, they are particularly
vulnerable to transcriptional inhibition (10–14,18). There-
fore, super-enhancers in Ewing sarcomamay provide mech-
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Figure 2. THZ1 selectively inhibitsRNAPII-mediated transcription inEwing sarcoma, (A,B) Immunoblotting analyses ofRNAP IICTDphosphorylation
in A673 and SKMNC cells treated either with THZ1 or DMSO at the indicated concentrations for the indicated durations. (C) Heatmap and (D) Box plots
showing changes in gene expression in A673 and SKNMC cells following treatment with either 50 or 200 nM THZ1 for 6 h. (E) Selected Gene ontology
(GO) functional categories of transcripts decreased over 2-fold in A673 and SKNMC cells following 50 nM THZ1 treatment for 6 h.
anistic explanation for THZ1-mediated selective transcrip-
tion inhibition.
To this end, we analyzed available H3K27ac ChIP-seq
data generated in 4 Ewing sarcoma cell lines and 3 primary
tumors (4,6), and identified super-enhancer-assigned genes
(Figure 3A; Supplementary Figure S1 and Datasets S2–8).
GO analysis revealed that super-enhancer-assigned genes
were significantly enriched in cellular processes representing
‘cancer hallmarks’ (22), such as cell proliferation, apoptosis,
motility and migration (Figure 3A; Supplementary Figure
S1). Importantly, Gene Set Enrichment analysis (GSEA)
showed that THZ1-sensitive transcripts were significantly
enriched in the gene sets associated with super-enhancers,
but not typical-enhancers (Figure 3B). Moreover, prefer-
ential downregulation of transcripts associated with super-
enhancers, but not typical-enhancers, was observed upon
THZ1 treatment (Figure 3C).
Super-enhancer elements are frequently associated with
and regulated by master transcription factors in normal
cell development (8,23). Since the disease-defining fusion
gene EWS-FLI1 orchestrates the transcriptional dysregu-
lation in Ewing sarcoma, we hypothesized that EWS-FLI1
also dominates the regulation of super-enhancers in Ew-
ing sarcoma. To this end, we used Pearson’s Chi-squared
test to compare the proportions of super-enhancer regions
to typical-enhancer regions containing EWS-FLI1 binding
peaks. Importantly, EWS-FLI1 peaks fell significantlymore
within super-enhancer regions in both A673 and SKNMC
cell lines (Figure 3D). Moreover, GGAA repeats, the estab-
lished active EWS-FLI1 binding motif in Ewing sarcoma
(4,6,24,25), were enriched in a much higher degree in super-
enhancer regions relative to typical-enhancer ones (Figure
3E). Importantly, we further performedGSEA in A673 and
SKNMC cells to interrogate gene expression profiles in ei-
ther the absence or presence of EWS-FLI1 knockdown, and
found that super-enhancer-associated transcripts were sig-
nificantly enriched among genes whose expressions were
altered by EWS-FLI1, compared with typical-enhancer-
associated transcripts (Figure 3F).
1260 Nucleic Acids Research, 2019, Vol. 47, No. 3
C  D  
F  E  
A  B  
Figure 3. Profiling of super-enhancer landscapes in Ewing sarcoma cell lines, (A) Hockey stick plots showing rank order of H3K27ac signals for all
enhancers in A673 and SKNMC cells. Inserted panels showing selected GO functional categories of super-enhancer-associated genes. (B) Gene Set En-
richment analysis (GSEA) of the fold changes of super-enhancer (SE)-associated transcripts following treatment with 50 nM THZ1 for 6 h in A673 and
SKNMC. (C) Box plots showing log2 fold changes of transcripts associated with typical-enhancer (TE) and SE upon 50 nM THZ1 treatment for 6 h in
A673 and SKNMC. (D, E) Pearson’s Chi-squared tests showed SE regions had significantly more (D) EWS-FLI1 binding peaks and (E) motif (GGAA
repeats) than TE regions. EWS-FLI1 ChIP-seq data are publicly accessible on NCBI GEO under the accession number ‘GSE61953′. (F) GSEA of the
fold changes of either SE- or TE-associated transcripts upon EWS-FLI1 depletion (48 hr) in A673 and SKNMC cells. Gene expression data for A673 and
SKNMC cells in either the presence or absence of EWS-FLI1 knockdown were also obtained from NCBI GEO (GSE61953).
These results suggested that partially under the regula-
tion of EWS-FLI1, super-enhancers mediate the superior
vulnerability of Ewing sarcoma cells to CDK7 inhibition,
and play key roles in the biology of Ewing sarcoma.
Identification of MEIS1 as a super-enhancer-associated gene
in Ewing sarcoma
In an attempt to screen robustly for super-enhancer-
associated genes functionally relevant in Ewing sarcoma bi-
ology, we required them to occur in at least three out of
four Ewing sarcoma cell lines and one out of three pri-
mary samples. This approach generated a total of 147 genes
(Supplementary Table S6), containing a number of known
Ewing sarcoma oncogenes such as CCND1, NKX2–2,
BCL11B and MYC (6,16,26–31) (Figure 4A; Supplemen-
tary Figure S2A). We also observed pro-growth factors
implicated in other cancer types but not yet character-
ized in Ewing sarcoma, such as MEIS1, APCDD1 and
IGF2BP1 (32–37) (Figures 4B and 6C; Supplementary Fig-
ure S2B). Importantly, enhancer profiles were highly simi-
lar between Ewing sarcoma cell lines and primary tumors,
which were also supported by additional markers such as
H3K4me1 (Figures 4A, B and 6C; Supplementary Figure
S2A, B). By re-analyzing the publically-available Hi-C data
of SKNMC cells, we confirmed extensive interactions be-
tween enhancers and promoters (indicated by red connect-
ing lines above the ChIP-seq profiles in Figure 4A, B).
Moreover, constituent elements within super-enhancer re-
gions were also noted to have frequent interactions, a char-
acteristics of active super-enhancers that was recently re-
ported (38). Additionally, in agreement with above analysis,
occupancy of EWS-FLI1 in many of these super-enhancers
was evident (e.g. NKX2–2, APCDD1, CCND1, Figures 4A
and 6C; Supplementary Figure S2A). Importantly, in sil-
ico analysis with Cancer Cell Line Encyclopedia (CCLE)
showed distinct expression patterns of many of these super-
enhancer-assigned genes in Ewing sarcoma (Figure 4C;
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Figure 4. Nomination of super-enhancer-associated transcripts in Ewing sarcoma, (A, B) ChIP-seq profiles of EWS-FLI1, H3K27ac, H3K4me1 and
H3K4me3 at representative super-enhancer-associated gene loci across Ewing sarcoma cell lines and primary tumors. Y axis represents the value of reads
per million per base pair (rpm/bp). Above the ChIP-seq profiles were interactions among cis-regulatory elements in SKNMC cells predicted by Hi-C from
ENCODE project, and visualized using public browser (http://promoter.bx.psu.edu/hi-c/index.html). (C) Data retrieved from CCLE project depicting
mRNA expression of representative super-enhancer-associated transcripts across various types of human cancer cells.
Supplementary Figure S2C), underscoring the capacity of
our approach to nominate lineage-specific transcripts and
potential oncogenes.
Among these 147 super-enhancer-associated transcripts,
wewere particularly interested inMEIS1, because the inten-
sity of its super-enhancer ranked first in SKNMC cells (Fig-
ure 3A), and it had prominent expression profiles in Ewing
sarcoma (Figure 4C).
MEIS1 is a homeodomain transcription factor ex-
tensively investigated in both normal and leukemic
hematopoiesis. In acute myeloid leukemia, overexpression
of MEIS1 has been consistently observed (36,39–43). Im-
portantly, in validating MEIS1 mRNA expression (Figure
4C), protein levels of MEIS1 were similarily high in Ewing
sarcoma cells, and were comparable with, or even higher
than that of leukemic cells; while in breast cancer cells,
expression of MEIS1 was low (Supplementary Figure S3).
Using luciferase reporter assay, we noted robust activity
of MEIS1 super-enhancer constituents (>1.5-fold over
control, P < 0.01) (Supplementary Figure S4). In addition,
immunoblotting confirmed high sensitivity of MEIS1 to
THZ1 treatment in Ewing sarcoma (Supplementary Figure
S5).
MEIS1 is a novel oncogenic factor in Ewing sarcoma
The biological relevance of MEIS1 in Ewing sarcoma
was next assessed. Importantly, knockdown of MEIS1
by shRNAs markedly decreased cell proliferation and in-
creased cell apoptosis (Figure 5A-C). Over-expression of
MEIS1 promoted colony growth of Ewing sarcoma cells
as measured by soft agar assays (Figure 5D). Furthermore,
on-target effect of shRNA-mediated knockdown was con-
firmed by rescue assays (Figure 5E).
We next tested the dependency of Ewing sarcoma cells
on MEIS1 in an in vivo setting. To this end, we generated
a cell line model in which MEIS1 expression could be si-
lenced by doxycycline (DOX)-inducible shRNA (A673-Tet-
shMEIS1) (Supplementary Figure S6). Xenograft tumors
were then established in nude mice by subcutaneous im-
plantation. After inoculation, either doxycycline (25 mg/kg
per day via oral gavage) or vehicle control (3% sucrose in
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Figure 5. Oncogenic function of MEIS1 in Ewing sarcoma, (A) MTT assay, (B) apoptosis assay and (C) soft-agar assay evaluating the knockdown effects
of MEIS1 on Ewing sarcoma cells. Error bars represent mean ± SD of three replicates (*P < 0.05, **P < 0.01, ***P < 0.001). Efficiency of MEIS1
knockdown in Ewing sarcoma cells was shown by immunoblotting assays. (D) Ewing sarcoma cells were stably transfected with either empty vector (EV)
or plasmid encodingMEIS1 (OE). Immunoblotting was performed to determineMEIS1 expression, and cell anchorage-independent growth was measured
by soft agar assay. Error bars represent mean ± SD of three replicates (**P < 0.01, *** P < 0.001). (E) A673 and EW8 cells stably expressing indicated
plasmids were infected again with either shMEIS1 or shRNA control (Scramble), and subjected to immunoblotting andMTT assays. Bars represent mean
± SD of three replicates (***P < 0.001). (F–G) Nude mice were inoculated subcutaneously with A673 cells stably expressing inducible MEIS1 shRNA
(A673-Tet-shMEIS1). Mice were randomly allocated to either doxycycline (DOX)-treated or vehicle-treated groups (n = 5 per group). (F) Representative
images and (G) weights of resected tumors at the end point (**P < 0.01).
drinking water, ad libitum) was administered to the mice for
the duration of the experiments. Importantly, silencing of
MEIS1 significantly inhibited xenograft tumor growth (Fig-
ure 5F, G; Supplementary Figure S6), corroborating the in
vitro results. Collectively, these data strongly suggested that
MEIS1 is a progrowth factor in Ewing sarcoma.
Further to understand the function of MEIS1 in the bi-
ology of Ewing sarcoma, ChIP-seq was performed using
MEIS1 antibody in A673 cells. This generated a genome-
wide occupancy profile of MEIS1 containing 1800 peaks
with high confidence (Supplementary Dataset S9).
Motif analysis revealed that both MEIS1 and HOXA9
consensus motifs experimentally determined in hematopoi-
etic cells were highly enriched in MEIS1-associated DNA
fragments (Figure 6A). This result was consistent with the
known functional interaction betweenMEIS1 andHOXA9
in hematopoietic cells, and stongly suggested the cognate
recognition motifs of MEIS1 in both hematopoietic and
Ewing sarcoma cells (44–46). Strikingly, the binding motif
of EWS-FLI1 in Ewing sarcoma was also significantly en-
riched in the MEIS1-binding regions (Figure 6A).
Indeed, approximately 24% of MEIS1 binding sites (433
of 1800) overlapped with 12% of those of EWS-FLI1 (433
of 3533) (P< 2.2e–16, Figure 6B). Through further integra-
tion with RNA-seq data in the presence of silencing EWS-
FLI1, we also found that a significant fraction (13.8%, 71
of 513) of ‘EWS-FLI1 direct target genes’ (genes bound by
EWS-FLI1 and changed in expression by more than 2-fold
in response to EWS-FLI1 knockdown, Supplementary Fig-
ure S7) were co-occupied by MEIS1 (Supplementary Fig-
ure S8 and Dataset S10). We validated the co-regulation of
MEIS1 andEWS-FLI1 on a number of these EWS-FLI1 di-
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Figure 6. MEIS1 andEWS-FLI1 directly co-bind super-enhancer regions ofAPCDD1, (A) HomerMotif Enrichment results of known transcription factor
binding motifs enriched at MEIS1 binding regions in A673 cells. (B) Venn diagram displaying the overlap between EWS-FLI1 and MEIS1 peaks in A673
cells. P value was calculated using Fisher’s exact test. (C) Integrative Genomics Viewer showing MEIS1, EWS-FLI1, H3K27ac, H3K4me1 and H3K4me3
occupancy in APCDD1 gene in A673 and SKNMC cells as well as primary tumors. Olive and purple bars indicate template regions subjected to ChIP-
qPCR experiments. (D-E) Confirmation of selected (D) MEIS1 and (E) EWS-FLI1 binding sites in APCDD1 locus by ChIP-qPCR. NC, negative control.
Error bars represent mean± SD of three replicates (n.s., statistically no significance, *P< 0.05, **P< 0.01, ***P< 0.001). (F–G) Either (F) EWS-FLI1 or
(G) MEIS1 was silenced in A673 and SKNMC cells, and antibodies against either (F) MEIS1 or (G) FLI-1 were used to determine the transcription fator
change in occupancy at selected regions of APCDD1 by ChIP-qPCR. Error bars represent mean ± SD of three replicates (n.s., statistically no significance,
*P < 0.05, **P < 0.01, ***P < 0.001).
rect target genes by qRT-PCR (Supplementary Figure S9).
Importantly, amongst these genes, there were established
EWS-FLI1 downstream targets functionally important for
Ewing sarcoma, such as STEAP1 and SOX5 (47,48). In ad-
dition, the co-occupancy ofMEIS1 and EWS-FLI1 was no-
table in many of them (examples shown in Figure 6C and
Supplementary Figure S10). These results indicated that
MEIS1 might functionally co-operate with EWS-FLI1 in
co-regulating the gene expression program in Ewing sar-
coma.
MEIS1 and EWS-FLI1 transcriptionally activate APCDD1
in Ewing sarcoma
To test further this hypothesis, focus was placed on one
of their mutually targeted genes: APCDD1. APCDD1 was
noted because: (i) its super-enhancer intensity ranked No.2
in SKNMC cells (Figure 3A); (ii) it was specifically upregu-
lated in EWS cells (Figure 4C) and (iii) it has been identified
as a tumor-promoting factor in colon cancer (34). Binding
peaks of MEIS1 and EWS-FLI1 on APCDD1 (which were
validated byChIP-qPCRassays, Figure 6D, E) were flanked
with high levels of H3K4me1 and H3K27ac modifications
(Figure 6C), strongly suggesting the positive regulation of
MEIS1 and EWS-FLI1 on APCDD1 transcription.
To test the potential functional interplay between
MEIS1 and EWS-FLI1 in the transcriptional regulation of
APCDD1, we silenced either of the transcription factors
and noted that binding of the other was significantly im-
paired (Figure 6F, G; Supplementary Figure S11). We next
cloned individual super-enhancer constituents (E2, E3, E4
and E5) of APCDD1 into the pGL3-Promoter luciferase re-
porter vector, and measured their activities by reporter as-
says. As shown in Supplementary Figure S12A and B, E2
and E4 were particularly active in both A673 and SKNMC
cells (> 1.5-fold over control, P < 0.01), while E3 and E5
had little activities. Importantly, enhancer activities of both
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E2 and E4 were significantly decreased upon depletion of
either MEIS1 or EWS-FLI1 in A673 and SKNMC cells
(Supplementary Figure S12C). Moreover, both the mRNA
and protein expressions of APCDD1 were substantially
suppressed when silencing MEIS1 or EWS-FLI1 (Figure
7A, B). These findings suggested that MEIS1 and EWS-
FLI1 may facilitate the recruitment of each other, and co-
operatively activate the transcription of APCDD1 by its en-
hancer elements E2 and E4.
Finally, we tested whether super-enhancer-driven
APCDD1 played a role in the biology of Ewing sar-
coma. Similar to MEIS1 silencing, APCDD1 depletion
reduced cell proliferation and anchorage-independent
growth of Ewing sarcoma cells (Figure 7C, D). Moreover,
APCDD1 depletion potently inhibited the growth of Ew-
ing sarcoma xenografts (Supplementary Figures S6, 13).
Considering the pro-growth functions observed in both
MEIS1 and APCDD1, and the activation of APCDD1
transcription by MEIS1 and EWS-FLI1, we speculated
that APCDD1 might function as a key factor mediating
the oncogenic role of MEIS1. To address this, APCDD1
was ectopically expressed in MEIS1-silenced cells. Impor-
tantly, APCDD1 restoration mitigated significantly the
growth-inhibitory effects triggered by MEIS1-silencing,
although ectopic expression of APCDD1 did not increase
MEIS1 expression level (Figure 7E). These results together
identified APCDD1 as a prominent tumor-promoting
factor associated with a super-enhancer in Ewing sarcoma.
Moreover, our data suggested that MEIS1 and EWS-FLI1
co-operatively activate APCDD1 transcription, thereby
promoting the malignant phenotype of Ewing sarcoma
cells (Figure 7F).
DISCUSSION
EWS-FLI1 is the central and driving force of tumorigenesis
and progression of Ewing sarcoma (1). Unfortunately, clin-
ical efficacy through directly targeting EWS-FLI1 has yet
to be achieved (49). Endeavors aimed at identifying addi-
tional dependencies in Ewing sarcoma are expected to pro-
vide novel therapeutic avenues for treatment of this cancer.
Here, we found that Ewing sarcoma cells were highly vul-
nerable to transcriptional perturbation achieved by CDK7
inhibition both in vitro and in vivo (Figure 1), which was in-
dependently confirmed by Iniguez et al.’s recent study (50).
We also observed clusters of genes, which were enriched in
key cellular functions associated with survival and prolifer-
ation of cancer cells, preferentially sensitive to THZ1 treat-
ment in Ewing sarcoma cells (Figure 2C, D).
To investigate whether THZ1-sensitive transcripts were
associated with any (epi)genomic features, the super-
enhancer landscape was comprehensively characterized in
Ewing sarcoma by analyzing published H3K27ac ChIP-seq
data in both Ewing sarcoma cell lines and primary tumors
(4,6). This approach highlighted the critical roles of super-
enhancer-associated genes in conferring sensitivity of Ew-
ing sarcoma cells to transcriptional inhibition (Figure 3B,
C).
It has become increasingly clear that super-enhancers in
cancer cells are often bound by master regulatory tran-
scription factors which mediate oncogenic gene expression
programs (6,51,52). In the context of Ewing sarcoma, we
demonstrated that in comparison with typical-enhancers,
super-enhancers had significantly more EWS-FLI1 bind-
ing peaks as well as its active motif, GGAA repeats (Fig-
ure 3D, E). Besides, super-enhancer-associated transcripts
were enriched among genes whose expression exhibited
the most profound changes following EWS-FLI1 depletion
(Figure 3F). These results further supported the notion that
super-enhancer transcripts are enriched in EWS-FLI1 tar-
get genes (6), and can be leveraged to identify novel onco-
genes in Ewing sarcoma.
Our integrated analysis generated a total of 147 genes,
which were associated with super-enhancers in both Ewing
sarcoma cell lines and primary samples.Notably, on this list,
we observed both well-established and candidate oncogenes
in Ewing sarcoma, with many of which displayed striking
Ewing sarcoma-specific expression profiles (e.g. LINGO1,
HOOK1, CITED2 and IGF2BP1) (53,54) (Supplementary
Figure S2C). Our results thus provided a category of poten-
tial oncogenic factors for future studies.
MEIS1 is a transcription factor belonging to the
Three Amino Acid Loop Extension (TALE) family of
homeodomain-containing proteins. Acting as a cofactor of
homeobox (HOX) family members, MEIS1 has been exten-
sively studied for its essential role in the differentiation of
hematopoietic cells (35,45,55–57). However, whether and
how MEIS1 functions in other tissue types is poorly ex-
plored. In acute leukemia, overexpression of MEIS1 has
been consistently observed (36,39–43), and level of MEIS1
is inversely correlated with prognosis of this hematopoietic
malignancy (58,59). In this study, we found that the expres-
sion level of MEIS1 in Ewing sarcoma cells was compara-
ble with, or even higher than, that of leukemic cells (Sup-
plementary Figure S3). Through a series of cellular phe-
notypical assays and in vivo experiment, we characterized
MEIS1 in Ewing sarcoma as both a driver of cell prolif-
eration and survival (Figure 5). Interestingly, recent pub-
lications revealed contributions of HOXD genes to the ma-
lignancy of Ewing sarcoma (60,61). Considering our ob-
servation from ChIP-seq experiment that the HOX motif
was strongly enriched inMEIS1-interactingDNA sequence
(Figure 6A), future exploration of the functional interplay
between MEIS1 and HOX genes in the context of Ewing
sarcoma will be of great interest.
Notably, another strongly enriched motif in MEIS1
ChIP-seq data was EWS-FLI1 (Figure 6A). Via analyzing
the ChIP-seq results of MEIS1 and EWS-FLI1, as well as
the RNA-seq results of EWS-FLI1 knockdown in A673
cells, we found approximately a quarter of MEIS1 peaks
shared the same genomic binding regions with EWS-FLI1
(Figure 6B). Meanwhile, 13.8% of ‘EWS-FLI1 direct tar-
get genes’ were also co-occupied by MEIS1 (Supplemen-
tary Figures S7, S8 and Dataset S10). Thus, we speculated
that in Ewing sarcoma, the disease-defining fusion pro-
tein EWS-FLI1 might act as a cell-type specific MEIS1-
interacting factor, facilitating and co-operatingwithMEIS1
in regulating the gene expression program. In addition, we
identified the super-enhancer-associated APCDD1, which
was uniquely expressed at high levels in Ewing sarcoma,
as a novel pro-growth gene transcriptionally activated by
MEIS1 and EWS-FLI1 in a co-operative fashion. Specifi-
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Figure 7. APCDD1 is co-regulated byMEIS1 and EWS-FLI1 andmediates the oncogenic role ofMEIS1. (A, B) Silencing of (A)MEIS1 or (B) EWS-FLI1
downregulated expression of both APCDD1 mRNA and protein. Error bars represent mean ± SD of three replicates (**P < 0.01, ***P < 0.001). (C, D)
APCDD1 knockdown potently (C) inhibited cell proliferation and (D) decreased colony formation. Error bars represent mean± SD of three replicates (*P
< 0.05, **P< 0.01, ***P< 0.001). (E) A673 and SKNMC cells stably expressing shMEIS1 were transiently transfected with plasmid encoding APCDD1,
and subjected to immunoblotting and MTT assays. Bars represent mean ± SD of three replicates (**P < 0.01). (F) Proposed model showing that MEIS1
and EWS-FLI1 co-operatively activate APCDD1 transcription, thereby promoting the malignant phenotype of Ewing sarcoma cells.
cally, MEIS1 and EWS-FLI1 both were recruited to super-
enhancer elements of APCDD1, thereby promoting tran-
scription of the latter (Figures 6C-G and 7; Supplementary
Figure S12).
APCDD1 is a transmembrane glycoprotein that is as-
sociated with the Wnt/-catenin signaling pathway. How-
ever, the functional regulation of APCDD1 on Wnt/-
catenin pathway is considerably cell type- and tissue
context-dependent (34,62,63). In this study, we showed
that APCDD1 knockdown increased the expression of
CDC25A, LRP6, LEF1 and NKD1, which are confirmed
targets of the canonical Wnt pathway in Ewing sar-
coma (64–68) (Supplementary Figure S14), implying that
APCDD1 might act as a Wnt inhibitor in this cancer. Nev-
ertheless, future investigations are needed to dissect its func-
tional mechanisms in Ewing sarcoma.
In summary, the current study provides comprehen-
sive analysis of super-enhancer-mediated transcriptional
dysregulation of Ewing sarcoma, and identifies MEIS1
as a novel super-enhancer-driven oncogene, which co-
operates with EWS-FLI1 in transcriptional regulation.
Importantly, our data suggest that targeting the super-
enhancer-associated oncogenic transcription program may
serve as a promising therapeutic method for Ewing sar-
coma, and highlight super-enhancer-associated genes as a
valuable resource for future research of the pathogenesis of
Ewing sarcoma.
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